| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H27N5 |
| Molecular Weight | 361.4833 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCCNC1=NC=CC2=C(C)C3=C(C=C12)C4=C(N3)C=CN=C4
InChI
InChIKey=LPHSYQSMAGVYNT-UHFFFAOYSA-N
InChI=1S/C22H27N5/c1-4-27(5-2)12-6-9-24-22-18-13-17-19-14-23-10-8-20(19)26-21(17)15(3)16(18)7-11-25-22/h7-8,10-11,13-14,26H,4-6,9,12H2,1-3H3,(H,24,25)
| Molecular Formula | C22H27N5 |
| Molecular Weight | 361.4833 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pazelliptine (previously known as BD 40 or SR 95225A) was developed as an antitumor drug that binds to the DNA sequence, preferable to G-C rich region and thus produces cellular DNA lesions. This drug was undergoing phase II trials in France for the treatment of cancer. However, this study was discontinued.
